PaQ (CeQur SA) is a simple to use patch-on device which provides set basal rates and bolus insulin on demand. PaQ was designed to minimize barriers to insulin therapy. In addition to feasibility of use, safety and efficacy (reported elsewhere), this study analyzed the impact of the use of PaQ on patient reported outcomes (PRO) including; barriers against insulin treatment, diabetes related distress and negative attitudes towards insulin therapy in twenty patients with type 2 diabetes (T2D) on a stable multiple daily injections (MDI) insulin regimen. This single center, open label, single arm study was comprised of three 2-week periods; baseline (MDI), transition from MDI to PaQ, and PaQ treatment. Three validated questionnaires were completed at the end of the baseline and PaQ treatment periods; Barriers to Insulin Treatment - Questionnaire (BIT), Problem Areas In Diabetes –Scale (PAID) and Insulin Treatment Appraisal Scale (ITAS). Nineteen patients (age 59 ±5 y, T2D duration 15±7 y, 21% female, A1C 7.7 ±0.7%) completed the questionnaires at the two measurement points. There was a strong and significant effect of PaQ in the mean BIT total score (2.5 to 2.1, difference (D)=0.4 ±0.6; p = .01, effect size (d) = 0.70). Patients perceived less hardship from insulin therapy (overall improvement d = 0.35), less stigmatization by insulin injection (overall improvement d=0.28) and less fear of hypoglycemia (overall reduction d=0.29). Diabetes related distress was slightly reduced (PAID 21.7 to 21.0, D=0.7 ±6.7, p = 0.79, d= 10). A non-significant reduction was also seen in the mean ITAS score (42.80 to 40.80, D=2.0 ±6.5, p = .20, d= 31). The study is limited by both the uncontrolled design and small sample size, however, the results and the moderate to large effect sizes suggest that the use of PaQ has beneficial and clinically relevant effects to overcome barriers to and negative appraisal of insulin treatment, without increasing other diabetes related distress.